Effect of chronic treatment with compound-326 on energy expenditure in DIO mice. by Hiroaki Yashiro (2231686)

The association between consistent habitual running or walking and a slow trajectory of estimated GFR decline (quartile 1)^b'*'. by Ronit Calderon-Margalit (584756)

AgrC biotinylation by Agr-ID inhibited the growth of <i>S. aureus</i>. (A) Schematic model for testing the growth of biotinylated <i>S. aureus</i> in LB medium and LB agar plate. (... by Lijuan Qian (3131523)

Image_5_Chronic Presence of Oligomeric Aβ Differentially Modulates Spine Parameters in the Hippocampus and Cortex of Mice With Low APP Transgene Expression.TIF by Mariya V. Hrynchak (8762793)

TIRF analyses of pericentrin-depleted MIN6 cells at non-stimulatory glucose concentration (2.5 mM) show increase in docked insulin granules and decrease at stimulatory glucose conc... by Agata Jurczyk (245201)

Effects of chronic treatment with compound-326 on PD markers and gene expression in WAT in DIO mice. by Hiroaki Yashiro (2231686)

Both the HRM and the HTM reproduce the key features of medfly mortality pattern: (i) increase, (ii) local maximum, (iii) U-shape, (iv) second local maximum, higher than the first o... by Yann Le Cunff (102173)

Effect of protein size on the relationship between site-specific evolutionary rates and distance to the nearest catalytic residue. by Benjamin R. Jack (2637040)

“…The addition of distance to a structural-constraints (RSA and WCN) model increases the accuracy of rate prediction near the active site up to shell 3 (17.5 Å) in small proteins and up to shell 5 (27.5 Å) in large proteins. …”

ODE modeling of WNT5A-EGF/AR signaling and experimental validation. by Zhiwei Ji (493628)

“…<p>(<b>A)</b> The effect of WNT5A on 22RV1 cell viability. …”

Parasite viability 5 days after the end of the infection. by Elaine Carvalho de Oliveira (11630455)

Schematic representation of the effects of stepwise bromination of the benzene ring of benzotriazole (Bt), including interdependence of the molecular volume (A) and pK_a (B) of the products with their IC₅₀ for inhibition of protein kinase CK2α: (a) Green arrows follow sequential bromination of the central vicinal C(5)/C(6) atoms, leading to a moderate decrease of pK_a and a large decrease in IC₅₀; (b) Red arrows illustrate the lesser effects of bromination of the peripheral C(4)/C(7) atoms, resulting in a significant decrease of pK_a, with virtually no gain in inhibitory activity; (c) Black lines link products with the same number of bromine atoms, but substantially differing in pK_a and IC₅₀, culminating in the di- and tri-brominated derivatives with inhibitory activities comparable to that of TBBt. by Romualda Wąsik (119538)

Effects of chronic treatment with compound-326 on plasma glucose and insulin during an OGTT, and HOMA-IR in DIO mice. by Hiroaki Yashiro (2231686)

Effects of chronic treatment with compound-326 on BW, calorie intake, and fat mass in DIO mice. by Hiroaki Yashiro (2231686)

Joint moment data from the lower limb joints. by Eric Yung-Sheng Su (13015474)

The Associations Between SDI and iNTS across 21 GBD Regions. A. by Yunjuan He (7107446)

Effects of chronic treatment with compound-326 on BW, calorie intake, and blood PD markers in DIO mice. by Hiroaki Yashiro (2231686)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)

Discovery of Novel <i>N</i>‑Hydroxy-1,2,4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis by Kan Yang (49193)